Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎ New York, NY
(646) 856-9261
info@inspirna.com

Shugaku Takeda, PhD

Principal Scientist

Shugaku leads Inspirna’s research and development efforts focused on biologics development. He received his Ph.D. from Washington University in St. Louis. He continued his oncology studies at Memorial Sloan-Kettering Cancer Center before joining Inspirna. His research focused on the transcriptional regulation of cell cycle progression and metastasis in cancers using cell culture and mouse tumor models, and screening and development of a small molecule inhibitor of Tasp1 as a novel therapeutic targeting cancer proliferation. Shugaku’s research discoveries have been published in leading journals including Nature, Nature Cell Biology, The Journal of Clinical Investigation, and Cancer Research.